Healthpeak Properties (DOC) AI Stock Analysis

• Market Cap: $13.54B
• Dividend Yield: 6.95%
• Average Volume (3M): 5.87M
• Price to Earnings (P/E): 48.0
• Beta (1Y): 0.62
• Revenue Growth: 23.65%
• EPS Growth: 12.82%
• Country: US
• Employees: 387
• Sector: Real Estate
• Sector Strength: 61
• Industry: REIT - Healthcare Facilities
• EPS (TTM): 0.05
• Shares Outstanding: 694,732,100
• 10 Day Avg. Volume: 5,240,571
• 30 Day Avg. Volume: 5,865,480
• PEG Ratio: 3.20
• Price to Book (P/B): 1.56
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 10.84
• Enterprise Value/Market Cap: 1.61
• Enterprise Value/Revenue: 2.08
• Enterprise Value/Gross Profit: 12.88
• Enterprise Value/Ebitda: 3.46
• 1Y Price Target: $21.58
• Price Target Upside: 13.28% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13

• Rating: 74 Outperform
• Price Target: $21.00 ▲(10.24%Upside)

Healthpeak Properties displays solid financial performance with robust revenue growth and cash flow management, though high leverage is a concern. The technical analysis suggests positive momentum, but caution is advised due to overbought indicators. Valuation is mixed with a high P/E ratio offset by a strong dividend yield. The earnings call reinforced confidence in key business segments, despite challenges in the Lab segment.

Positive Factors

Dividend Increase

The dividend increased by 1.7% to $0.305, marking the first increase since February 2016.

Partnerships and Collaborations

DOC announced a new partnership with Hines, indicating potential growth and collaboration opportunities.

Share Buybacks

The company repurchased $94 million in shares year-to-date, signaling confidence in its own stock value.

Negative Factors

Earnings Guidance

FY25 Adj-FFO guidance was maintained at $1.84/sh, below Street/BMO's $1.85.

Investment Environment

The transition from distressed lab investments to share buybacks highlights a challenging macro environment for VC funding and lab leasing.

Lab Market Challenges

There is an expected deceleration in lab SSNOI growth, reflecting challenges in the Life Science market.

Healthpeak Properties Business Overview & Revenue Model

Company Description

Healthpeak Properties, Inc. (NYSE: PEAK) is a fully integrated real estate investment trust (REIT) that specializes in owning, developing, and managing a diversified portfolio of healthcare real estate in the United States. The company primarily focuses on three core sectors: Life Science, Medical Office, and Continuing Care Retirement Communities (CCRCs). Healthpeak Properties aims to deliver long-term growth and value for its shareholders by leveraging its expertise in healthcare real estate and maintaining a strong portfolio of high-quality properties.

How the Company Makes Money

Healthpeak Properties generates revenue primarily through leasing its healthcare real estate properties to tenants in the life science, medical office, and senior housing sectors. The company earns rental income from long-term lease agreements with tenants, which include healthcare providers, research institutions, and other businesses operating in the healthcare industry. Additionally, Healthpeak may engage in property development and redevelopment projects, which can enhance the value of its portfolio and generate additional income through the sale or leasing of newly developed spaces. Strategic partnerships and joint ventures with healthcare operators and investors also contribute to its revenue by expanding its reach and enhancing its market presence in key healthcare markets.

Healthpeak Properties Financial Statement Overview

Summary

Healthpeak Properties demonstrates solid financial health with strong revenue growth and efficient cash flow management. While profitability metrics are improving, high leverage is a potential risk that needs monitoring. Overall, the company is well-positioned in its industry with opportunities for further operational enhancements.

Income Statement

Healthpeak Properties shows a strong revenue growth trajectory with a significant increase from 2024 to TTM (Trailing-Twelve-Months). The gross profit margin remains healthy, indicating good control over cost of sales. While net profit margin shows improvement over time, there is room for optimization in operational efficiency to enhance profitability further.

Balance Sheet

The company's debt-to-equity ratio is relatively high, indicating leveraged operations. However, the return on equity is decent, highlighting effective use of shareholder equity. The equity ratio is stable, suggesting a balanced approach to asset management, but high debt levels could pose future risks.

Cash Flow

Operating cash flow is robust with consistent free cash flow growth, signaling strong cash generation capabilities. The operating cash flow to net income ratio is favorable, demonstrating efficient cash conversion. However, attention to investing and financing activities is recommended to maintain liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.70B	2.18B	2.06B	1.90B	1.64B
Gross Profit	1.63B	1.28B	1.20B	1.12B	862.33M
EBITDA	1.61B	1.27B	1.39B	970.63M	1.13B
Net Income	243.14M	306.01M	500.45M	505.54M	413.56M
Balance Sheet
Total Assets	19.94B	15.70B	5.10B	5.18B	4.41B
Cash, Cash Equivalents and Short-Term Investments	119.82M	138.99M	7.73M	9.88M	2.52M
Total Debt	9.02B	7.08B	1.92B	2.02B	1.51B
Total Liabilities	10.88B	8.77B	2.10B	2.19B	1.67B
Stockholders Equity	8.40B	6.35B	2.87B	2.84B	2.64B
Cash Flow
Free Cash Flow	1.07B	956.24M	218.53M	214.99M	199.41M
Operating Cash Flow	1.07B	956.24M	258.40M	247.56M	233.30M
Investing Cash Flow	-113.80M	-576.75M	-38.47M	-603.22M	-201.91M
Financing Cash Flow	-941.42M	-337.30M	-222.07M	363.03M	-31.22M

Healthpeak Properties Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 19.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DOC, the sentiment is Positive. The current price of 19.05 is above the 20-day moving average (MA) of 18.19, above the 50-day MA of 17.53, and below the 200-day MA of 19.19, indicating a neutral trend. The MACD of 0.37 indicates Negative momentum. The RSI at 67.15 is Neutral, neither overbought nor oversold. The STOCH value of 88.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DOC.

Healthpeak Properties Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WELL	79 Outperform	$105.70B	174.25	3.52%	1.66%	23.31%	36.07%
SBRA	77 Outperform	$4.38B	31.18	5.15%	6.53%	7.81%	179.16%
OHI	75 Outperform	$11.30B	24.47	10.53%	6.87%	10.56%	45.37%
DOC	74 Outperform	$13.54B	48.01	3.26%	6.95%	23.65%	12.82%
VTR	68 Neutral	$31.23B	203.93	1.36%	2.76%	10.00%	―
Sector *	64 Neutral	$6.87B	17.44	-1.93%	6.95%	4.65%	-24.33%
HR	59 Neutral	$5.71B	―	-6.83%	7.64%	-7.26%	18.45%

Healthpeak Properties Corporate Events

Healthpeak Properties Reports Q2 2025 Financial Results

Healthpeak Properties reported its second quarter 2025 financial results, showing a net income of $0.05 per share and a 3.5% growth in Total Merger-Combined Same-Store Cash NOI. The company executed significant lease agreements and entered into new development agreements to support outpatient expansion, while also achieving sustainability milestones and earning prestigious industry awards.

The most recent analyst rating on (DOC) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Healthpeak Properties stock, see the DOC Stock Forecast page.

Healthpeak Properties to Join BofA Healthcare Panel

John Thomas, Vice Chair of Healthpeak Properties, is set to participate in a panel discussion at the BofA Securities 2025 Healthcare Conference on May 14, 2025. This participation highlights Healthpeak’s ongoing engagement with industry events, potentially impacting its visibility and stakeholder relations.

The most recent analyst rating on (DOC) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Healthpeak Properties stock, see the DOC Stock Forecast page.

Healthpeak Properties Approves Employee Stock Purchase Plan

On January 30, 2025, Healthpeak Properties, Inc. adopted an Employee Stock Purchase Plan (ESPP) to allow eligible employees to purchase company stock at a discount, aligning their interests with those of shareholders. The ESPP was approved at the annual meeting on April 24, 2025, where all board nominees were elected, executive compensation was approved, and Deloitte & Touche LLP was ratified as the independent auditor.